Business Context and Reporting Period
Company: MiMedx Group, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2010
Status: Development Stage Enterprise
Business Overview: MiMedx is an integrated developer, manufacturer, and marketer of patent-protected biomaterial-based products for the orthopedics and spine markets. The company operates under the "Repair, don't replace" mantra, utilizing proprietary technologies such as CollaFix and HydroFix. As of the reporting date, the company has not emerged from the development stage and relies on equity and debt financing to fund operations.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2010 |
Nine Months Ended Sep 30, 2010 |
Balance Sheet Sep 30, 2010 |
|---|---|---|---|
| Net Sales (Revenue) | $108,027 | $544,956 | N/A |
| Cost of Products Sold | $539,697 | $1,355,210 | N/A |
| Gross Margin | (Negative) | (Negative) | N/A |
| Net Loss | $(2,854,442) | $(8,693,096) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $428,493 |
| Total Assets | N/A | N/A | $6,847,122 |
| Total Liabilities | N/A | N/A | $1,143,645 |
| Stockholders' Equity | N/A | N/A | $5,703,477 |
| Long-Term Debt | N/A | N/A | $0 (Converted) |
Note: The company reported a negative gross margin due to high fixed costs during commercial manufacturing ramp-up and low production volumes relative to market prices.
Material Changes vs. Prior Period
- Revenue Growth: The company generated $108,027 in revenue for the three months ended September 30, 2010, compared to $0 in the same period in 2009. For the nine months, revenue was $544,956 versus $0 in 2009. This marks the beginning of commercial sales for HydroFix Vaso Shield (US) and HydroFix Spine Shield (International).
- Debt Conversion: On March 31, 2010, the company converted all outstanding 3% Convertible Senior Secured Promissory Notes (face value $3,472,000 plus accrued interest) into 7,135,114 shares of common stock. Consequently, long-term debt was eliminated from the balance sheet as of September 30, 2010.
- Operating Expenses: Research and Development (R&D) expenses decreased by approximately 11.2% ($106,000) in the three-month period compared to 2009, primarily due to personnel transfers to manufacturing. Selling, General, and Administrative (SG&A) expenses increased by 8.3% ($121,000) due to higher stock-based compensation.
- Cash Position: Cash and cash equivalents decreased from $2,653,537 at December 31, 2009, to $428,493 at September 30, 2010, reflecting a net cash outflow from operating activities of $6,171,456 for the nine-month period.
Guidance, Outlook, Risks, and Unusual Items
- Liquidity and Going Concern: Management explicitly states that the company's ability to continue as a going concern is dependent on securing additional financing. As of September 30, 2010, cash was $428,000. Subsequent to the period end (October/November 2010), the company secured $400,000 in convertible notes from directors and $244,000 in a government grant, and raised $2,000,000 in a private placement. Management estimates these funds will sustain operations through December 2010.
- Future Funding Needs: The company intends to extend its current private placement to fund ongoing operations beyond December 2010 and to accelerate its business plan. Failure to raise additional funds could prevent the company from developing products or obtaining regulatory approvals.
- Regulatory Progress: The FDA granted 510(k) clearance for additional thicknesses and sizes of the HydroFix Vaso Shield in June 2010. The company continues to pursue regulatory clearance for other technologies.
- Unusual Items: The 2009 comparative periods included significant non-cash financing expenses ($1.3M for registration rights waivers and $683k for warrants) which were not present in the 2010 periods, distorting year-over-year expense comparisons.
Investor Verification Checklist
- Cash Runway: Verify the status of the private placement and the $400,000 convertible notes from directors to confirm if the company has secured funding beyond the estimated December 2010 runway.
- Gross Margin Trajectory: Monitor future quarters to determine if production volume increases sufficiently to absorb fixed manufacturing costs and achieve a positive gross margin.
- Dilution Risk: Review the impact of the recent private placement and warrant exercises on the total share count and potential future dilution from the convertible notes held by directors.
- Regulatory Milestones: Track the progress of FDA clearances for the CollaFix product line and other technologies in clinical development.
- Revenue Sustainability: Assess whether the initial revenue from HydroFix products is recurring and if the expansion of the sales distribution network is yielding consistent growth.